



Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE		Application Number	1,280
STATEMENT BY APPLICANT		Filing Date	January 24, 2005
 (attach many sheets as necessary)		First Named Inventor	Caulfield, Michael J. et al.
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	20930P
1	of	3	

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number  (if known)		
		WO	01/059157	Millipore Corporation	08/16/2001
		WO	00/77518	The Gov. of the USA, represented by the Sec. DHHS; Flow Applications, Inc.	12/21/2000
		WO	00/22431	Feldberg, S. et al.	04/20/2000
		WO	98/54354	The Trustees of the University of PA	12/03/1998
		WO	96/12819	Spiral Biotech, Inc.	05/02/1996

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., inc., 09/05/2003

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/522,280
Filing Date	January 24, 2005
First Named Inventor	Caulfield, Michael J. et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	20930P

Sheet 2 of 3

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/leb/		Abruzzo, G. et al. "Evaluation of the Echinocandin Antifungal MK-0991 (L-743,872): Efficacies in Mouse Models of Disseminated Aspergillosis, Candidiasis, and Cryptococcosis", Antimicrobial Agents and Chemotherapy, 1997, Vol. 41, pp. 2333-2338
		Anderson, E. et al. "Safety and Immunogenicity of Meningococcal A and C Polysaccharide Conjugate Vaccine in Adults", Infection and Immunity, 1994, Vol. 62, pp. 3391-3395
		Bartizal, K. et al. "In Vitro Preclinical Evaluation Studies with the Echinocandin Antifungal MK-0991 (L-743,872)", Antimicrobial Agents and Chemotherapy, 1997, Vol. 41, pp. 2326-2332
		Esposito, A. et al. "An assessment of the factors contributing to the killing of type 3 <i>Streptococcus pneumoniae</i> by human polymorphonuclear leukocytes <i>in vitro</i> ", APMS, 1990, Vol. 98, pp. 111-121
		Freeman, A. et al. "Effect of processing parameters on the feasibility and operational stability of immobilized viable microbial cells", Enzyme and Microbial Technology, 1998, Vol. 23, pp. 335-345
		Guckian, J. et al. "The Role of Opsonins in Recovery from Experimental Pneumococcal Pneumonia", The Journal of Infectious Diseases, 1980, Vol. 142, pp. 175-190
		Horikoshi, K. "Discovering novel bacteria, with an eye to biotechnological applications", Current Opinion in Biotechnology, 1995, Vol. 6, pp. 292-297
		Kaniuk, A. et al. "Specific IgG Subclass Antibody Levels and Phagocytosis of Serotype 14 Pneumococcus Following Immunization", Scandinavian Journal of Immunology, 1992, Vol. 36, Suppl. 11, pp. 96-98
		Kolmer, J. et al. "The Opsonic Activity of Fresh Normal Serum Alone and in Combination with Antimeningitis Serum for Meningococci", The Journal of Immunology, 1918, Vol. 3, pp. 157-175
		Lin, J. et al. "Chromogenic Assay Measuring Opsonophagocytic Killing Capacities of Antipneumococcal Antisera", Clinical and Diagnostic Laboratory Immunology, 2001, Vol. 8, pp. 528-533
		Liu, X. et al. "High-throughput imaging of bacterial colonies grown on filter plates with application to serum bactericidal assays", Journal of Immunological Methods, 2004, Vol. 292, pp. 187-193
		Loferer, H. et al. "Integrated bacterial genomics for the discovery of novel antimicrobials", Drug Discovery Today, 2000, Vol. 5, pp. 107-114
		Lortan, J. et al. "Relationship of <i>in vitro</i> phagocytosis of serotype 14 <i>Streptococcus pneumoniae</i> to specific class and IgG subclass antibody levels in healthy adults", Clinical and Experimental Immunology, 1993, Vol. 91, pp. 54-57
		Maslanka, S. et al. "Standardization and a Multilaboratory Comparison of <i>Neisseria meningitidis</i> Serogroup A and C Serum Bactericidal Assays", Clinical and Diagnostic Laboratory Immunology, 1997, Vol. 4, pp. 156-167
✓		Milagres, L. et al. "Immune Response of Brazilian Children to a <i>Neisseria meningitidis</i> Serogroup B Outer Membrane Protein Vaccine: Comparison with Efficacy", Infection and Immunity, 1994, Vol. 62, pp. 4419-4424

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/03/2003

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/522,280	
			Filing Date	January 24, 2005	
			First Named Inventor	Caulfield, Michael J. et al.	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	20930P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/leb/		Mittelman, M. et al. "Bacterial Cell Size And Surface Charge Characteristics Relevant to Filter Validation Studies", PDA Journal of Pharmaceutical Science & Technology, 1998, Vol. 52, pp. 37-42
		Nahm, M. et al. "A Modified Farr Assay Is More Specific than ELISA for Measuring Antibodies to <i>Streptococcus pneumoniae</i> Capsular Polysaccharides", The Journal of Infectious Diseases, 1996, Vol. 173, pp. 113-118
		Obaro, S. et al. "Defective antibody-mediated opsonisation of <i>S. pneumoniae</i> in high risk patients detected by flow cytometry", Immunology Letters, 1996, Vol. 49, pp. 83-89
		Quartaert, S. et al. "Assignment of Weight-Based Antibody Units to a Human Antipneumococcal Standard Reference Serum, Lot 89-S", Clinical and Diagnostic Laboratory Immunology, 1995, Vol. 2, pp. 590-597
		Romero-Steiner, S. et al. "Standardization of an Opsonophagocytic Assay for the Measurement of Functional Antibody Activity against <i>Streptococcus pneumoniae</i> Using Differentiated HL-60 Cells", Clinical and Diagnostic Laboratory Immunology, 1997, Vol. 4, pp. 415-422
		Schiffman, G. et al. "A Radioimmunoassay for Immunologic Phenomena in Pneumococcal Disease and for the Antibody Response to Pneumococcal Vaccines", Journal of Immunological Methods, 1980, Vol. 33, pp. 133-144
		Sveum, R. et al. "A quantitative fluorescent method for measurement of bacterial adherence and phagocytosis", Journal of Immunological Methods, 1986, Vol. 90, pp. 257-264
		van Reis, R. et al. "Membrane separations in biotechnology", Current Opinion in Biotechnology, 2001, Vol. 12, pp. 208-211
		Vernacchoi, L. et al. "Comparison of an Opsonophagocytic Assay and IgG ELISA to Assess Responses to Pneumococcal Polysaccharide and Pneumococcal Conjugate Vaccines in Children and Young Adults with Sickle Cell Disease", The Journal of Infectious Diseases, 2000, Vol. 181, pp. 1162-1166
		Vioarsson, G. et al. "Opsonization and Antibodies to Capsular and Cell Wall Polysaccharides of <i>Streptococcus pneumoniae</i> ", The Journal of Infectious Diseases, 1994, Vol. 170, pp. 592-599
		Winkelstein, J. et al. "The Role of C3 as an Opsonin in the Early Stages of Infection (38815)", Proceedings of the Society for Experimental Biology and Medicine, 1975, Vol. 149, pp. 397-401
✓		Zangwill, K. et al. "Duration of Antibody Response after Meningococcal Polysaccharide Vaccination in US Air Force Personnel", The Journal of Infectious Diseases, 1994, Vol. 169, pp. 847-852

Examiner Signature	/Lora E Barnhart/	Date Considered	06/19/2007
--------------------	-------------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003